Effect of iron chelation on inflammatory joint disease.
AUTOR(ES)
Andrews, F J
RESUMO
Mild iron deficiency induced by treatment with the iron chelator desferrioxamine reduced the incidence and severity of joint inflammation associated with adjuvant disease in rats but did not alter the local primary inflammatory response or the systemic sequelae. Both rats treated with desferrioxamine and control rats showed increased levels of alpha 1 acid glycoprotein, characteristic pathological changes in the liver and inguinal lymph nodes, and the primary inflammatory response at the site of injection. Histology, microfocal radiography, and gross assessment of the joints, however, showed a suppression or reduction in soft tissue swelling and bone erosion in the rats treated with desferrioxamine. This is a novel observation suggesting an apparently selective influence of iron on joint mediated inflammation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1002129Documentos Relacionados
- Oxygen radicals, nitric oxide and human inflammatory joint disease.
- Echocardiographic diastolic abnormalities of the left ventricle in inflammatory joint disease.
- Total hip replacement using the Charnley prosthesis in inflammatory joint disease.
- Immunoglobulin classes in plasma cells of the synovial membrane in chronic inflammatory joint disease.
- Chelation therapy for cardiovascular disease. Review and commentary.